How many drugs treat Nephrotic syndrome?

Drug Landscape tracks 10 marketed treatments for Nephrotic syndrome (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/nephrotic-syndrome.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nephrotic syndrome — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nephrotic syndrome (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Nephrotic syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Solu-Medrol	methylprednisolone succinate	Pfizer	Corticosteroid	Glucocorticoid receptor	1959-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Medrol	methylprednisolone	Generic (originally Upjohn/Pfizer)	Glucocorticoid (corticosteroid)	Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor	1957-10-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Deltasone	prednisone	Generic (originally Schering)	Corticosteroid [EPC]	Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor	1955-01-01
Solu-Cortef	hydrocortisone succinate	Pfizer	Corticosteroid	Glucocorticoid receptor	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortifoam	HYDROCORTISONE ACETATE	Pfizer	Corticosteroid	Corticosteroid-binding globulin	1951-01-01
prednison	prednison	Wen Zhang		Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Nephrotic syndrome
Pfizer · 3 drugs in Nephrotic syndrome
Generic (originally Schering) · 2 drugs in Nephrotic syndrome
Generic (originally Upjohn/Pfizer) · 1 drug in Nephrotic syndrome
Hannover Medical School · 1 drug in Nephrotic syndrome
Leiden University Medical Center · 1 drug in Nephrotic syndrome
University of Zurich · 1 drug in Nephrotic syndrome
Wen Zhang · 1 drug in Nephrotic syndrome
Generic (originally Merck) · 1 drug in Nephrotic syndrome
Generic (originally Merck/Upjohn) · 1 drug in Nephrotic syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Nephrotic syndrome:

Cite this brief

Drug Landscape (2026). Nephrotic syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nephrotic-syndrome. Accessed 2026-06-10.

Nephrotic syndrome full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing